Media coverage about Pulmatrix (NASDAQ:PULM) has been trending positive recently, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pulmatrix earned a news sentiment score of 0.31 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Pulmatrix (NASDAQ PULM) remained flat at $2.36 on Monday. The stock had a trading volume of 39,533 shares. The company’s market capitalization is $45.13 million. Pulmatrix has a 12 month low of $0.50 and a 12 month high of $6.98. The stock’s 50-day moving average is $2.56 and its 200-day moving average is $2.61.
Pulmatrix (NASDAQ:PULM) last issued its quarterly earnings results on Friday, May 5th. The biotechnology company reported ($0.21) EPS for the quarter. Pulmatrix had a negative return on equity of 164.91% and a negative net margin of 3,328.91%. On average, equities research analysts expect that Pulmatrix will post ($4.13) earnings per share for the current fiscal year.
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical stage biopharmaceutical company developing inhaled therapies to address serious pulmonary disease. The Company’s product pipeline is focused on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with lung disease, including cystic fibrosis.
Receive News & Ratings for Pulmatrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.